CFM
BCAB icon

Catalyst Funds Management’s BioAtla BCAB Stock Holding History

Catalyst Funds Management’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-226
Closed -$6.68K – 471
2024
Q4 		$6.68K Hold
226
– – ﹤0.01% 296
2024
Q3 		$19.9K Hold
226
– – ﹤0.01% 1084
2024
Q2 		$15.5K Buy
+226
New +$26.9K ﹤0.01% 769

Other funds holding BCAB

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Catalyst Funds Management's BCAB Position: Q1 2025 in Review

Catalyst Funds Management sold out of BioAtla (BCAB) in Q1 2025, closing a stake of 226 shares — an estimated $6.68K sold.

Catalyst Funds Management first reported a position in BCAB in Q2 2024 and held it in 3 quarters. The position peaked at $19.9K in Q3 2024. 41 funds tracked by Wall St. Rank hold BCAB as of Q1 2025.

  • Catalyst Funds Management reported no remaining BioAtla position as of Q1 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 226 BioAtla shares in Q1 2025, an estimated $6.68K.
  • Catalyst Funds Management first reported a position in BioAtla in Q2 2024 and held it in 3 quarters.
  • Catalyst Funds Management's BioAtla position peaked at $19.9K in Q3 2024.
  • 41 funds tracked by Wall St. Rank held BioAtla as of Q1 2025.

Based on Catalyst Funds Management's 13F filing for Q1 2025, filed 14 May 2025.